Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Net Income | 7.05% | 21.46% | 25.14% | 38.88% | 30.61% |
| Total Depreciation and Amortization | -20.98% | 33.54% | -38.19% | -14.57% | -29.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 174.25% | -13.33% | 90.67% | -54.38% | -244.78% |
| Change in Net Operating Assets | 132.94% | 300.42% | -203.31% | -89.95% | -66.32% |
| Cash from Operations | 95.33% | 91.66% | 23.66% | 23.13% | -118.06% |
| Capital Expenditure | -- | -- | -- | 100.00% | 101.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 87.27% | -1,250.00% | -- | -57.58% | -89.66% |
| Cash from Investing | -101.22% | -2,200.00% | -- | 89.73% | 697.92% |
| Total Debt Issued | -- | -- | -- | -100.00% | -7.83% |
| Total Debt Repaid | 112.12% | -30.52% | -32.17% | -34.09% | -36.36% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 1,608.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.89% | -136.51% | -108.72% | -101.47% | 20.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.10% | 87.08% | -3.27% | -1,497.59% | 13.13% |